Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Financing Activities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Cash from Financing Activities for 15 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 163.17% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.7 million, a 377.49% decrease, with the full-year FY2024 number at $1.5 million, down 21.47% from a year prior.
  • Cash from Financing Activities was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, down from -$174000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $14.8 million in Q4 2021 to a low of -$1.7 million in Q1 2025.
  • A 5-year average of $1.4 million and a median of $96500.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 295800.0% in 2021, then crashed 186.1% in 2025.
  • NovaBay Pharmaceuticals' Cash from Financing Activities stood at $14.8 million in 2021, then plummeted by 79.49% to $3.0 million in 2022, then plummeted by 100.86% to -$26000.0 in 2023, then surged by 2026.92% to $501000.0 in 2024, then crashed by 363.27% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Cash from Financing Activities are -$1.3 million (Q3 2025), -$174000.0 (Q2 2025), and -$1.7 million (Q1 2025).